$7.44
N/A
Last update: Nov 10, 4:00 PM
MapLight Therapeutics Inc
MPLTNASDAQ
MapLight Therapeutics fell 50.6% from $15.07 to $7.44, behind the S&P 500's +9.8%. Its worst day was Jul 27 (−72.9%), and its low came Nov 5 at $6.22.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-37.18 missed the $-1.36 estimate on $0.00 revenue.
+8.4% · S&P 500 +0.1%
EPS of $-2.47 missed the $-0.92 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
+6.0% · S&P 500 −1.8%
MapLight Therapeutics shares rose 21.3%, while the S&P 500 rose 0.6%.
+21.3% · S&P 500 +0.6%
EPS of $-1.34 missed the $-1.08 estimate on $0.00 revenue.
−1.9% · S&P 500 −1.2%
MapLight Therapeutics closed at its highest level of the year, 164.1% above where the year started.
+3.3% · S&P 500 +0.8%
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with
−72.9%, the year's worst day, on 8M shares, the year's heaviest volume · S&P 500 0.0%
EPS of $-1.32 beat the $-1.33 estimate on $0.00 revenue.
+1.5% · S&P 500 −0.2%
MapLight Therapeutics closed at its lowest level of the year, 58.7% below where the year started.
−7.3% · S&P 500 −4.4%
Where it ended: a close of $7.44 on Nov 10, 2026. Up next: Q3 2026 earnings on Dec 3, 2026 (EPS est. $-1.13).
Nothing in the past 12 months.
All MPLT dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MPLT and SPY from Benzinga historical bars. Not investment advice.
